Reuters logo
BRIEF-Thrombogenics achieves important milestone in development of THR-149, novel plasma kallikrein inhibitor for diabetic macular edema
April 20, 2017 / 5:52 AM / 6 months ago

BRIEF-Thrombogenics achieves important milestone in development of THR-149, novel plasma kallikrein inhibitor for diabetic macular edema

April 20 (Reuters) - Thrombogenics NV:

* Achieves important milestone in the development of THR-149, a novel plasma kallikrein inhibitor for diabetic macular edema

* Has an exclusive license to undertake pre-clinical and clinical development

* Bicycle Therapeutics receives development milestone payments and royalties on sales of products resulting from collaboration Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below